Akkermansia muciniphila probiotic for body weight in overweight and obese adults
Tests a heat-treated Akkermansia muciniphila supplement against placebo in overweight or obese adults.
Plain-language title generated from the registry record
Registry title: Probiotic for Weight Management in Overweight and Obese Adults
Key facts
- Where
- Luoyang, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07507929, who can take part
Where in China
- The School of Food and Bioengineering, Henan University of Science and TechnologLuoyang, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wecare Probiotics Co., Ltd.
- Trial code
- NCT07507929
- Record updated
- 2 April 2026
- Original description
To evaluate the impact of pasteurized Akkermansia muciniphila Akk11 capsules versus placebo on body composition (including body weight, BMI, body fat percentage, waist-to-hip ratio, wrist circumference, visceral fat area, and basal metabolic rate) and serum lipid parameters (TC, LDL-C, HDL-C, and TG) in overweight and obese adults.Read full original descriptionShow less
Effectiveness and Safety of Inactivated Akkermansia Muciniphila Akk11 (34B) on Weight and Energy Metabolism in Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
To evaluate the impact of pasteurized Akkermansia muciniphila Akk11 capsules versus placebo on body composition (including body weight, BMI, body fat percentage, waist-to-hip ratio, wrist circumference, visceral fat area, and basal metabolic rate) and serum lipid parameters (TC, LDL-C, HDL-C, and TG) in overweight and obese adults.
Inclusion: Body mass index (BMI) ≥ 24 kg/m²; Able and willing to provide written informed consent; Willing to comply with the study protocol and required restrictions, including adherence to a low-carbohydrate, energy-restricted diet; No intention to conceive from 14 days prior to screening until 6 months after study completion, and agreement to use effective contraception during this period.
Exclusion: Recent use of products with similar functions to the investigational product that may interfere with study outcomes; Use of antibiotics within 3 months prior to screening; Inability to comply with the study protocol, including failure to take the investigational product as required or attend scheduled follow-up visits; History of psychiatric or neurological disorders, celiac disease, lactose intolerance, or known allergies; Diagnosis of irritable bowel syndrome (IBS), ulcerative colitis, liver cirrhosis, or diabetes mellitus; Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study; Pregnant or breastfeeding women, or those planning to become pregnant during the study period; Smoking more than 10 cigarettes per day.